Developer docs
API playgroundTry for free, no card

Search company profiles

Jafron Biomedical Co

Full company profile

uuid003hxxa

Namestring
Jafron Biomedical Co
Legal namestring
健帆生物科技集团股份有限公司
Websiteurl
jafron.com
Company typeenum
Public
Founded yearint
2002
Descriptiontext

Jafron Biomedical Co is a Chinese medical device company specializing in blood purification, with a specific focus on resin-based whole-blood hemoperfusion technology. Founded in 2002 via management buyout of the loss-making Lizhu Biomedical Materials Factory and listed on the Shenzhen Stock Exchange ChiNext (stock code 300529), the company pioneered the world's first resin-based whole-blood hemoperfusion system using proprietary neutral macroporous adsorption resin. The company operates from Zhuhai, China, with additional production bases in Beijing/Tianjin and Hubei, a Shenzhen Center opened in January 2026 for international business, and global distribution across 90+ countries and 8,000+ hospitals (6,000+ in China).

The product portfolio centers on the HA-series disposable hemoperfusion cartridges — HA130, KHA130, and pHA130 for nephrology/ESRD; HA330, HA380, and CA330 for critical care and sepsis; HA280 and DNA230 for immunology and autoimmune disease; BS330 and HA330-II for liver failure support under the DPMAS (Double Plasma Molecular Adsorption System) modality. The proprietary neutral macroporous resin chemistry, combined with biocompatible collodion coatings and specialized pore structures, enables adsorption of middle/large molecule toxins and protein-bound toxins directly from whole blood without plasma separation. Capital equipment includes the DX-10 intelligent multi-mode blood purification system (CRRT machine), the JF-800A hemoperfusion machine, and the Future F20 blood purifier. Dialysis products include high/low-flux dialyzers, tubing circuits, and dialysate solutions. The company also operates the Aiduoduo (爱多多) digital health management platform offering kidney-disease patient education tools, nutritional supplements, and kidney-disease insurance — forming an integrated device-consumable-pharmaceutical-insurance-digital stack around the patient.

Jafron's revenue model combines high-margin recurring disposable consumable sales (6 million+ units annually; cartridges are single-use and required per treatment session for chronic dialysis patients, creating volume-driven repeat demand) with capital equipment revenue (DX-10 priced at 148,000 RMB/unit). Distribution is executed through direct enterprise field sales to hospitals via academic-promotion specialists in China and through country-level distributors internationally, supported by a 300,000+ annual interactions customer service center, continuous clinical training, and 3,000+ clinical publications including 300+ SCI papers. The company holds 387 patents (105 invention patents), ISO 13485 GMP certification for 12 consecutive years, CE mark, and the National Manufacturing Single Champion Enterprise designation. Domestic market share is 70%+ in the hemoperfusion segment. Key risk: the recent revenue trajectory shows decline from a 2021 peak, partially recovering into 2025, suggesting exposure to industry-level pricing pressure from China's DRG/DIP reimbursement reform and hemoperfusion-specific centralized procurement dynamics.

Short descriptiontext

Jafron Biomedical Co is a Chinese public medical device company (Shenzhen ChiNext, ticker 300529) that designs, manufactures, and sells proprietary resin-based hemoperfusion cartridges plus blood purification equipment, serving 8,000+ hospitals globally across nephrology, hepatology, critical care, and immunology indications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersZhuhai, China
HQ citystring
Zhuhai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
blood purification devices, hemoperfusion cartridges, dialysis consumables, medical device manufacturing, blood purification equipment
Industry2 codes
PRIMARYHLAHAKAH
Renal Replacement Therapy Consumables (Bloodlines, Filters, Cartridges)
SECONDARYHLAFAMAG
Transfusion Medicine & Immunohematology (Blood Bank)
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Blood Purification Medical Devices
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Disposable Blood Hemoperfusion Devices
TypeOne Time License
Description

High-margin consumable products including HA series hemoperfusion devices for nephrology, hepatology, critical care, and immune diseases. Single-use products requiring repeated purchases from dialysis patients. Revenue generated from 500+ annual clinical uses and 6000+ hospital customers.

jafron.com
2Blood Purification Equipment (DX-10)
TypeOne Time License
Description

Capital equipment sales including DX-10 blood purification machines priced at 148,000 yuan per unit. Equipment enables CRRT, artificial liver, and immune adsorption treatments in hospitals. 4000+ units installed across 2000+ hospitals.

jafron.com
3Dialysis Consumables and Accessories
TypeOne Time License
Description

Complete dialysis product line including dialysis tubing, high/low flux dialyzers, dialysate powder/liquid, and JF-800A hemoperfusion machines. Products support combination therapies for comprehensive kidney disease management.

jafron.com
4Chronic Disease Management Services
TypeSubscription Recurring
Description

Health management services, nutritional products, health supplements, kidney disease insurance (爱多多), and intelligent management systems for comprehensive patient care throughout the disease journey.

jafron.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain
Pricing details2 tiers
1DX-10 Blood Purification Machine - National unified retail price
ModelUnit PricingBilling cadenceOne time/ perpetual license
Notes

148,000 yuan per unit (14.8万元/台) as national unified suggested retail price under 'Precision Craftsmanship Universal Benefit Action' initiative

jafron.com
2HA130 Hemoperfusion Device - Cost efficiency advantage
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Single treatment cost reduced to 1/3 of international similar products. Originally launched to replace expensive plasma separation at significantly lower price point

jafron.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1爱多多健康管理
Description

肾科全病程健康管理服务品牌,提供医护患教数智化管理工具及专业健康管理团队

jafron.com
+1 more record
Core offering1 text field

Jafron Biomedical Co manufactures and sells proprietary blood purification medical devices and consumables, centered on resin-based disposable hemoperfusion cartridges (HA series) and multi-mode blood purification equipment (DX-10). The company also produces dialysis consumables (dialyzers, tubing, dialysate), plasma separation devices, immune adsorbers, and runs a digital patient health management platform for kidney disease patients.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Jafron Biomedical Co is a vertically integrated medical device company specializing in blood purification. Its portfolio spans a unified ecosystem of proprietary hemoperfusion consumables, blood purification equipment, dialysis products, and digital health management services. The core product line centers on HA-series disposable hemoperfusion cartridges (HA130, KHA130, pHA130 for kidney disease; HA330, HA380, CA330 for critical care; HA280 for immune diseases; HA330-II for liver support), which use proprietary neutral macroporous adsorption resin to clear toxins. The BS330 plasma bilirubin adsorber and DNA230 immune adsorber extend into liver and autoimmune applications. Equipment includes the DX-10 multi-mode blood purification system (CRRT), JF-800A hemoperfusion machine, and Future F20 blood purifier. Dialysis products include dialyzers (high/low flux), tubing circuits, and dialysate solutions. The company also operates the Aiduoduo (爱多多) digital health management platform offering patient management tools, kidney disease insurance, and nutritional supplements — forming a 'device耗材-药品-保险-慢病管理' full-chain ecosystem around the patient.

Product and service1 record
1HA130 Disposable Blood Hemoperfusion Cartridge (HA130 一次性使用血液灌流器)
Scale indicator11 records

Each record includes

Type, Value, Description, Source

Recent move18 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Asahi Kasei Medical
TypeDirect peer
Description

Japanese subsidiary of Asahi Kasei Corporation manufacturing dialysis membranes, plasma fractionation, and blood purification devices (e.g., Leucocephron for selective adsorption). Directly comparable as a resin/membrane-based blood purification technology company serving the same nephrology and critical care customers as Jafron.

TypeDirect peer
Description

Japanese chemical/medical company with blood purification products including selective plasma exchange (Liposorber for LDL apheresis) and immunoadsorption columns. Comparable as a resin-based selective blood purification technology company targeting autoimmune and lipid disorders — directly competing with Jafron's HA280 and DNA230 immunoadsorption products.

TypeEmerging player
Description

US company developing the Seraph 100 blood filter for pathogen removal in bloodstream infections. Comparable as an emerging single-platform blood purification device company targeting critical care applications that overlap with Jafron's HA-series critical care cartridges.

4Nipro Corporation
TypeBroad incumbent
Description

Japanese medical device manufacturer with significant dialyzer and dialysis equipment business, including hollow-fiber membranes and dialysate solutions. Comparable as a vertically integrated dialysis consumable supplier targeting the same nephrology market segment as Jafron's dialysis product line.

TypeBroad incumbent
Description

Global dialysis services and products leader operating 4000+ dialysis centers and manufacturing dialyzers, CRRT machines, and related consumables. Comparable as the dominant incumbent in renal replacement therapy that Jafron's hemoperfusion cartridges complement alongside standard hemodialysis.

TypeDirect peer
Description

US-based company developing CytoSorb cytokine adsorption cartridges for sepsis, cytokine storm, and critical care blood purification. Directly comparable as a specialty blood purification company with a single-product technology platform addressing the same sepsis/cytokine storm clinical use case as Jafron's CA330 and HA380.

TypeDirect peer
Description

Japanese division of Toray Industries manufacturing cellulose and synthetic dialysis membranes, hemoconcentrators, and CRRT filters. Comparable as a specialty blood purification materials company with proprietary membrane/adsorption technology serving nephrology and critical care — directly overlapping with Jafron's consumable product positioning.

TypeEmerging player
Description

Canadian company developing the Toraymyxin PMX endotoxin removal cartridge and a sepsis diagnostic. Comparable as an emerging blood purification player targeting sepsis (similar to Jafron's CA330/HA380) with regulatory-stage products competing for similar ICU applications.

TypeBroad incumbent
Description

US medical device company with extensive CRRT and dialysis portfolio (e.g., Prismax system, HF440 dialyzer). Comparable through overlapping critical care blood purification products (CA330-style cytokine adsorption equivalents) and global hospital sales channels targeting the same ICU/nephrology customer base.

10B. Braun Avitum
TypeOthers
Description

German B. Braun's dialysis and blood purification division manufacturing hemodialysis machines, dialyzers, and CRRT systems for global hospital customers. Comparable as a major European-headquartered incumbent serving the same hospital nephrology and ICU segments.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat7 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Jafron Biomedical Co

Blood Purification Medical Devicesjafron.com

Jafron Biomedical Co is a Chinese public medical device company (Shenzhen ChiNext, ticker 300529) that designs, manufactures, and sells proprietary resin-based hemoperfusion cartridges plus blood purification equipment, serving 8,000+ hospitals globally across nephrology, hepatology, critical care, and immunology indications.

What Jafron Biomedical Co does

Jafron Biomedical Co is a Chinese medical device company specializing in blood purification, with a specific focus on resin-based whole-blood hemoperfusion technology. Founded in 2002 via management buyout of the loss-making Lizhu Biomedical Materials Factory and listed on the Shenzhen Stock Exchange ChiNext (stock code 300529), the company pioneered the world's first resin-based whole-blood hemoperfusion system using proprietary neutral macroporous adsorption resin. The company operates from Zhuhai, China, with additional production bases in Beijing/Tianjin and Hubei, a Shenzhen Center opened in January 2026 for international business, and global distribution across 90+ countries and 8,000+ hospitals (6,000+ in China).

The product portfolio centers on the HA-series disposable hemoperfusion cartridges — HA130, KHA130, and pHA130 for nephrology/ESRD; HA330, HA380, and CA330 for critical care and sepsis; HA280 and DNA230 for immunology and autoimmune disease; BS330 and HA330-II for liver failure support under the DPMAS (Double Plasma Molecular Adsorption System) modality. The proprietary neutral macroporous resin chemistry, combined with biocompatible collodion coatings and specialized pore structures, enables adsorption of middle/large molecule toxins and protein-bound toxins directly from whole blood without plasma separation. Capital equipment includes the DX-10 intelligent multi-mode blood purification system (CRRT machine), the JF-800A hemoperfusion machine, and the Future F20 blood purifier. Dialysis products include high/low-flux dialyzers, tubing circuits, and dialysate solutions. The company also operates the Aiduoduo (爱多多) digital health management platform offering kidney-disease patient education tools, nutritional supplements, and kidney-disease insurance — forming an integrated device-consumable-pharmaceutical-insurance-digital stack around the patient.

Jafron's revenue model combines high-margin recurring disposable consumable sales (6 million+ units annually; cartridges are single-use and required per treatment session for chronic dialysis patients, creating volume-driven repeat demand) with capital equipment revenue (DX-10 priced at 148,000 RMB/unit). Distribution is executed through direct enterprise field sales to hospitals via academic-promotion specialists in China and through country-level distributors internationally, supported by a 300,000+ annual interactions customer service center, continuous clinical training, and 3,000+ clinical publications including 300+ SCI papers. The company holds 387 patents (105 invention patents), ISO 13485 GMP certification for 12 consecutive years, CE mark, and the National Manufacturing Single Champion Enterprise designation. Domestic market share is 70%+ in the hemoperfusion segment. Key risk: the recent revenue trajectory shows decline from a 2021 peak, partially recovering into 2025, suggesting exposure to industry-level pricing pressure from China's DRG/DIP reimbursement reform and hemoperfusion-specific centralized procurement dynamics.

Jafron Biomedical Co firmographics

Firmographics
Name
Jafron Biomedical Co
Legal name
健帆生物科技集团股份有限公司
Website
https://jafron.com
Company type
Public
Founded year
2002
Operating status
Operating
Headcount range
101–250 employees
Short description
Jafron Biomedical Co is a Chinese public medical device company (Shenzhen ChiNext, ticker 300529) that designs, manufactures, and sells proprietary resin-based hemoperfusion cartridges plus blood purification equipment, serving 8,000+ hospitals globally across nephrology, hepatology, critical care, and immunology indications.
Ownership category
akta.pro rank

Jafron Biomedical Co industry classification

Industry
Product category
Blood Purification Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAKAH
Renal Replacement Therapy Consumables (Bloodlines, Filters, Cartridges)
SECONDARYHLAFAMAG
Transfusion Medicine & Immunohematology (Blood Bank)

Keywords

  • Blood purification devices
  • Hemoperfusion cartridges
  • Dialysis consumables
  • Medical device manufacturing
  • Blood purification equipment

Where Jafron Biomedical Co is headquartered

Location

Headquarters

HQ city
Zhuhai
HQ country
China
HQ region
Asia

Offices7 records

Markets served

Jafron Biomedical Co business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

  1. Disposable Blood Hemoperfusion Devices: High-margin consumable products including HA series hemoperfusion devices for nephrology, hepatology, critical care, and immune diseases. Single-use products requiring repeated purchases from dialysis patients. Revenue generated from 500+ annual clinical uses and 6000+ hospital customers.
  2. Blood Purification Equipment (DX-10): Capital equipment sales including DX-10 blood purification machines priced at 148,000 yuan per unit. Equipment enables CRRT, artificial liver, and immune adsorption treatments in hospitals. 4000+ units installed across 2000+ hospitals.
  3. Dialysis Consumables and Accessories: Complete dialysis product line including dialysis tubing, high/low flux dialyzers, dialysate powder/liquid, and JF-800A hemoperfusion machines. Products support combination therapies for comprehensive kidney disease management.
  4. Chronic Disease Management Services: Health management services, nutritional products, health supplements, kidney disease insurance (爱多多), and intelligent management systems for comprehensive patient care throughout the disease journey.

Pricing tiers

ModelBillingPrice
Unit PricingOne time/ perpetual licenseDX-10 Blood Purification Machine - National unified retail price
Unit PricingPay-as-you-goHA130 Hemoperfusion Device - Cost efficiency advantage

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Jafron Biomedical Co product offering

Product offering

Core offering

Jafron Biomedical Co manufactures and sells proprietary blood purification medical devices and consumables, centered on resin-based disposable hemoperfusion cartridges (HA series) and multi-mode blood purification equipment (DX-10). The company also produces dialysis consumables (dialyzers, tubing, dialysate), plasma separation devices, immune adsorbers, and runs a digital patient health management platform for kidney disease patients.

Product overview

Jafron Biomedical Co is a vertically integrated medical device company specializing in blood purification. Its portfolio spans a unified ecosystem of proprietary hemoperfusion consumables, blood purification equipment, dialysis products, and digital health management services. The core product line centers on HA-series disposable hemoperfusion cartridges (HA130, KHA130, pHA130 for kidney disease; HA330, HA380, CA330 for critical care; HA280 for immune diseases; HA330-II for liver support), which use proprietary neutral macroporous adsorption resin to clear toxins. The BS330 plasma bilirubin adsorber and DNA230 immune adsorber extend into liver and autoimmune applications. Equipment includes the DX-10 multi-mode blood purification system (CRRT), JF-800A hemoperfusion machine, and Future F20 blood purifier. Dialysis products include dialyzers (high/low flux), tubing circuits, and dialysate solutions. The company also operates the Aiduoduo (爱多多) digital health management platform offering patient management tools, kidney disease insurance, and nutritional supplements — forming a 'device耗材-药品-保险-慢病管理' full-chain ecosystem around the patient.

Differentiator

Problem solved

Functional benefit

Brands

  • 爱多多健康管理: 肾科全病程健康管理服务品牌,提供医护患教数智化管理工具及专业健康管理团队
  • DPMAS

Products and services

  • HA130 Disposable Blood Hemoperfusion Cartridge (HA130 一次性使用血液灌流器)

Companies that use Jafron Biomedical Co

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Jafron Biomedical Co technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Jafron Biomedical Co partnerships and signals

Strategic signal

Scale indicators11 records

Recent moves18 records

Expansion highlights6 records

Jafron Biomedical Co competitors and assessment

Company assessment

Direct peers

  • Asahi Kasei Medical: Japanese subsidiary of Asahi Kasei Corporation manufacturing dialysis membranes, plasma fractionation, and blood purification devices (e.g., Leucocephron for selective adsorption). Directly comparable as a resin/membrane-based blood purification technology company serving the same nephrology and critical care customers as Jafron.
  • Kaneka Corporation: Japanese chemical/medical company with blood purification products including selective plasma exchange (Liposorber for LDL apheresis) and immunoadsorption columns. Comparable as a resin-based selective blood purification technology company targeting autoimmune and lipid disorders — directly competing with Jafron's HA280 and DNA230 immunoadsorption products.
  • CytoSorbents Corporation: US-based company developing CytoSorb cytokine adsorption cartridges for sepsis, cytokine storm, and critical care blood purification. Directly comparable as a specialty blood purification company with a single-product technology platform addressing the same sepsis/cytokine storm clinical use case as Jafron's CA330 and HA380.
  • Toray Medical: Japanese division of Toray Industries manufacturing cellulose and synthetic dialysis membranes, hemoconcentrators, and CRRT filters. Comparable as a specialty blood purification materials company with proprietary membrane/adsorption technology serving nephrology and critical care — directly overlapping with Jafron's consumable product positioning.

Emerging players

  • ExThera Medical: US company developing the Seraph 100 blood filter for pathogen removal in bloodstream infections. Comparable as an emerging single-platform blood purification device company targeting critical care applications that overlap with Jafron's HA-series critical care cartridges.
  • Spectral Medical: Canadian company developing the Toraymyxin PMX endotoxin removal cartridge and a sepsis diagnostic. Comparable as an emerging blood purification player targeting sepsis (similar to Jafron's CA330/HA380) with regulatory-stage products competing for similar ICU applications.

Broad incumbents

  • Nipro Corporation: Japanese medical device manufacturer with significant dialyzer and dialysis equipment business, including hollow-fiber membranes and dialysate solutions. Comparable as a vertically integrated dialysis consumable supplier targeting the same nephrology market segment as Jafron's dialysis product line.
  • Fresenius Medical Care: Global dialysis services and products leader operating 4000+ dialysis centers and manufacturing dialyzers, CRRT machines, and related consumables. Comparable as the dominant incumbent in renal replacement therapy that Jafron's hemoperfusion cartridges complement alongside standard hemodialysis.
  • Baxter International: US medical device company with extensive CRRT and dialysis portfolio (e.g., Prismax system, HF440 dialyzer). Comparable through overlapping critical care blood purification products (CA330-style cytokine adsorption equivalents) and global hospital sales channels targeting the same ICU/nephrology customer base.

Others

  • B. Braun Avitum: German B. Braun's dialysis and blood purification division manufacturing hemodialysis machines, dialyzers, and CRRT systems for global hospital customers. Comparable as a major European-headquartered incumbent serving the same hospital nephrology and ICU segments.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

Jafron Biomedical Co compliance and trust

Trust signal

Compliance3 records

Jafron Biomedical Co financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Jafron Biomedical Co leadership team

Management profile

Number of profiles

Profiles6 records

Jafron Biomedical Co subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

Jafron Biomedical Co funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Jafron Biomedical Co M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jafron Biomedical Co

What does Jafron Biomedical Co do?

Jafron Biomedical Co manufactures and sells proprietary blood purification medical devices and consumables, centered on resin-based disposable hemoperfusion cartridges (HA series) and multi-mode blood purification equipment (DX-10). The company also produces dialysis consumables (dialyzers, tubing, dialysate), plasma separation devices, immune adsorbers, and runs a digital patient health management platform for kidney disease patients.

Is Jafron Biomedical Co a public or private company?

Jafron Biomedical Co is a public company. It is classified as public and is currently operating.

When was Jafron Biomedical Co founded?

Jafron Biomedical Co was founded in 2002. It employs 101 to 250 people.

Where is Jafron Biomedical Co based?

Jafron Biomedical Co is headquartered in Zhuhai, China, in the Asia region.

How does Jafron Biomedical Co make money?

Four revenue lines are on record. Disposable Blood Hemoperfusion Devices are the primary driver. The others are blood Purification Equipment (DX-10), dialysis Consumables and Accessories and chronic Disease Management Services.

Who are Jafron Biomedical Co's main competitors?

Direct peers on record are Asahi Kasei Medical, Kaneka Corporation, CytoSorbents Corporation and Toray Medical. Emerging players are ExThera Medical and Spectral Medical. Broad incumbents are Nipro Corporation, Fresenius Medical Care and Baxter International. B. Braun Avitum is listed as an others.

Does Jafron Biomedical Co have an API?

No public API is recorded for Jafron Biomedical Co.

What industry is Jafron Biomedical Co in?

Jafron Biomedical Co's product category is Blood Purification Medical Devices. Its primary akta.pro industry code is HLAHAKAH, Renal Replacement Therapy Consumables (Bloodlines, Filters, Cartridges), with a secondary code of HLAFAMAG, Transfusion Medicine & Immunohematology (Blood Bank). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals